CAR-T and TIL cell therapy
Cell therapies for lymphoma, leukaemia, myeloma and melanoma, sometimes available more quickly than at home.
Read more →← Conditions
Condition guide
Blood cancer treatment options in China
This page covers lymphoma, leukaemia and myeloma. It explains standard care at home and the cell therapies in China that may be relevant after earlier treatment.
About blood cancers
Blood cancers start in the bone marrow or lymph system. Lymphoma affects lymph tissue, leukaemia affects blood-forming cells, and myeloma affects plasma cells in the marrow.
Many types respond well to treatment, and some can be controlled for years. Others come back or stop responding, and that is when people start looking for other options.
What standard care at home usually looks like
Treatment depends on the exact type and genetic features. It may include chemotherapy, targeted drugs, immunotherapy, radiation or stem cell transplant. Some slow-growing types are watched without treatment at first.
For lymphoma, leukaemia and myeloma that return, CAR-T therapy is available in Canada for certain types and after certain earlier treatments. Access depends on the province, criteria and capacity at the treating centre.
Options in China that may be relevant
New cancer antibodies and ADCs
Medicines approved in China first, for selected cancers.
Read more →Gene therapy for blood disorders
A brief mention: gene therapy for haemophilia B and thalassaemia. These are not cancers, and we describe them on their own page.
Read more →Second opinions
Review of your case by a haematology team.
Read more →Who might consider looking abroad
Some people have relapsed disease and are not eligible for CAR-T at home, or face a long wait. Others want to know whether a Chinese product could suit their specific type. Cell therapies may differ in design, target and approval status from those you know.
These treatments carry serious risks: cytokine release syndrome, nerve-related side effects, infections and low blood counts. Teams need to be experienced, with intensive care available. Not everyone responds, and responses may not last.
Who should not travel, or should wait
- People with fast-growing disease who need urgent treatment at home
- People with active infection, or who need frequent transfusions
- People whose disease is not well controlled and who are unfit for long flights
- People who have not yet used the established options for their type
- Anyone not able to stay for the full treatment and monitoring period
Records to gather
- Diagnosis report with the exact subtype and genetic or flow cytometry results
- Bone marrow biopsy and imaging reports
- Full treatment list with dates and responses
- Details of any stem cell transplant
- Recent blood counts, kidney, liver and heart tests
- Infection history, including hepatitis B and HIV status
Prepare and send your records
Send records securely
Upload your reports for specialist review.
Read more →Medical records guide
Requesting pathology and lab records.
Read more →Flying with cancer
Travel safety with low blood counts.
Read more →Frequently asked questions
Is CAR-T available in Canada?
Yes, for certain lymphomas, leukaemias and myeloma, when specific criteria are met. Ask your haematologist whether you qualify and how long the wait is.
What is TIL therapy?
It uses immune cells taken from a tumour, grown in the lab, then returned to the patient. It is used mainly for melanoma, not for most blood cancers.
How long would I stay?
Cell therapy often takes several weeks for manufacturing and monitoring. The treating team gives a timeline after review.
Do you coordinate gene therapy?
Yes, for haemophilia B and thalassaemia. These are inherited blood disorders, not cancers. See the gene therapy page for details.
Do not delay standard treatment. Blood cancers can change quickly, and your haematologist should stay involved. Licensed doctors make every treatment decision. We coordinate and cannot guarantee eligibility or outcomes.
Related pages
Sources: Canadian Cancer Society, Treatments for non-Hodgkin lymphoma · Canadian Cancer Society, Treatments for multiple myeloma
Last reviewed: 12 November 2026. This page is general information, not medical advice.
Sino Health Link is an independent coordination service, not a hospital. We do not diagnose, prescribe or treat. Licensed doctors make all medical recommendations and decisions with you.